High-dose, weekly erlotinib is not an effective treatment in EGFR-mutated non-small cell lung cancer-patients with acquired extracranial progressive disease on standard dose erlotinib

Eur J Cancer. 2014 May;50(7):1399-401. doi: 10.1016/j.ejca.2014.02.005. Epub 2014 Feb 28.

Authors

J L Kuiper¹, D A M Heideman², E Thunnissen², A W van Wijk³, P E Postmus³, E F Smit³

Affiliations

¹ Department of Pulmonary Diseases, VU University Medical Center, Amsterdam, The Netherlands. Electronic address: jl.kuiper@vumc.nl.
² Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands.
³ Department of Pulmonary Diseases, VU University Medical Center, Amsterdam, The Netherlands.

PMID: 24582911
DOI: 10.1016/j.ejca.2014.02.005

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Agents / administration & dosage*
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / pathology
Disease Progression
ErbB Receptors / genetics*
Erlotinib Hydrochloride
Humans
Lung Neoplasms / drug therapy*
Meningeal Neoplasms / drug therapy
Meningeal Neoplasms / secondary*
Protein Kinase Inhibitors / administration & dosage*
Quinazolines / administration & dosage*

Substances

Antineoplastic Agents
Protein Kinase Inhibitors
Quinazolines
Erlotinib Hydrochloride
EGFR protein, human
ErbB Receptors